Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 23;13:1034880. doi: 10.3389/fimmu.2022.1034880

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Dankers, Northcott, Bennett, D’Cruz, Sherlock, Gearing, Hertzog, Russ, Miceli, Scheer, Fujishiro, Hayakawa, Ikeda, Morand and Jones

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Type I IFN inhibits GILZ expression in human and mouse. (A) Healthy PBMC were treated with 1000 IU IFNα for 1 or 3 hours (left panel), or with 100 IU or 1000 IU for 3 hours (right panel), after which GILZ expression was analysed by qPCR. n=3-5, pooled from at least three independent experiments. (B) GILZ expression in splenocytes from WT or IFNα-overexpressing mice (GSE123549, n=2). (C) GILZ expression in PBMC from MS patients, before and 4 or 24 hours after injection of 500 µg IFNβ (GSE138064, n=25-26). *p<0.05, **p<0.01, ***p<0.001. ns, Not significant.